Clinical Trials on Clostridium Difficile-Associated Diarrhea in Ireland

Total 19 results

Pfizer

Completed

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

Clostridium Difficile Associated Disease

United States
Pfizer

Completed

A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years

Clostridium Difficile Associated Disease

United States
Pfizer

Completed

Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age

Clostridium Difficile Associated Disease

United States
Pfizer

Completed

Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study

Clostridium Difficile Associated Disease

United States
Microbiome Health Research Institute
Brown University; Tufts Medical Center; Indiana University; Edward Hospital

Terminated

Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection (STOOL)

Clostridium Difficile

United States
Seres Therapeutics, Inc.
Syneos Health

Completed

SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) (ECOSPOR)

Clostridium Difficile

United States
Astellas Pharma Europe Ltd.
Merck Sharp & Dohme LLC

Completed

A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population (EXTEND)

Clostridium Difficile

Greece, Spain, Russian Federation, Denmark, Austria, Belgium, Croatia, Czechia, Finland, France, Germany, Hungary, Ireland, Italy, Poland, Portugal, Romania, Slovenia, Sweden, Switzerland, Turkey, United Kingdom
The Miriam Hospital

Unknown

Gut Microbiota Changes After Fecal Microbiota Transplantation

Clostridium Difficile Infection

United States
Colleen Kelly

Unknown

Fecal Transplant for Relapsing C. Difficile Infection

Clostridium Difficile

United States
Finch Research and Development LLC.

Completed

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff (PRISM3)

Clostridium Difficile Infection Recurrence

Canada, United States
Finch Research and Development LLC.
Medpace, Inc.

Completed

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection (PRISM-EXT)

Clostridium Difficile Infection | Recurrent Clostridium Difficile Infection | C. Diff | CDI | Recurrent C. Diff | rCDI | C. Difficile | Recurrent CDI | FMT | Fecal Microbiota | Fecal Transplant

United States, Canada
Summit Therapeutics

Completed

To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection (Ri-CoDIFy 2)

Clostridioides Difficile Infection

United States, Spain, France, Canada, Belgium, Israel, Chile, Belarus, Latvia, Germany, Romania, Lithuania, Mexico, Czechia, Estonia, Georgia, Peru
Pfizer

Completed

Clostridium Difficile Vaccine Efficacy Trial (Clover)

Clostridium Difficile Infection

United States, Spain, Belgium, Taiwan, Japan, Portugal, Colombia, Korea, Republic of, Poland, Australia, Germany, Canada, Argentina, Bulgaria, Chile, Czechia, Finland, France, Hungary, Peru, Slovakia, Sweden, United Kingdom
Synthetic Biologics Inc.

Completed

A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI

Clostridium Infections | Clostridium Difficile

United States, Bulgaria, Canada, Hungary, Poland, Romania, Serbia
American Gastroenterological Association
University of Pennsylvania; University of California, San Diego; University of... and other collaborators

Recruiting

Fecal Microbiota Transplant National Registry (FMT)

Clostridium Difficile Infection | Gut Microbiome | Fecal Microbiota Transplantation

United States, Canada
Sanofi Pasteur, a Sanofi Company

Terminated

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

Clostridium Difficile Infection

Sweden, United States, Mexico, Philippines, Singapore, Germany, France, Canada, Australia, Peru, Colombia, Brazil, Costa Rica, Denmark, Dominican Republic, Finland, Guatemala, Japan, Korea, Republic of, Panama, Poland, Puerto Rico, ... and more
Bausch Health Americas, Inc.

Completed

A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

Diarrhea | Clostridium Infections

United States
Genzyme, a Sanofi Company

Completed

A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea

Diarrhea | Clostridium Enterocolitis

Australia, Belgium, France, Spain, Germany, Portugal, Switzerland, Austria, United Kingdom, Ireland, Czech Republic, Denmark, Norway, Sweden
Seres Therapeutics, Inc.

Completed

ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection

Clostridioides Difficile Infection

United States, Canada

Clinical Trials on Clostridium Difficile-Associated Diarrhea in Ireland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations